SCHEMBL30135547

SCHEMBL30135547

CC(C)(C)OC(=O)N1C[C@@H](F)C[C@H]1[C@@H](O)c1nc2ccccc2o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP9 Q86TI2 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
HTRA1 Q92743 1/20 0.34
HSF1 Q00613 1/20 0.34
NAAA Q02083 1/20 0.33
ITGB1 P05556 1/20 0.33
ITGA4 P13612 1/20 0.33
HDAC3 O15379 3/20 0.33
HDAC4 P56524 3/20 0.33
HDAC1 Q13547 3/20 0.33
HDAC7 Q8WUI4 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24928636 1.00 DPP4 (0.39) DPP4MEN1KMT2ADPP8DPP9
SCHEMBL24928632 0.82 EPHX2 (0.42) MEN1KMT2ALMNA
SCHEMBL30135545 0.79 MEN1 (0.41) DPP4MEN1KMT2ADPP8DPP9
SCHEMBL29774811 0.71 CFD (0.46) DPP4MEN1KMT2ASMN1; SMN2HTRA1
SCHEMBL20329747 0.71 CFD (0.46) DPP4MEN1KMT2ASMN1; SMN2HTRA1
SCHEMBL18554204 0.71 CFD (0.46) DPP4MEN1KMT2ASMN1; SMN2HTRA1
SCHEMBL18554205 0.71 CFD (0.46) DPP4MEN1KMT2ASMN1; SMN2HTRA1
SCHEMBL20329750 0.71 CFD (0.46) DPP4MEN1KMT2ASMN1; SMN2HTRA1
SCHEMBL31328545 0.71 NR1H2 (0.37) DPP4DPP8DPP9HTRA1
SCHEMBL29273287 0.71 NR1H2 (0.37) DPP4DPP8DPP9HTRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335569-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3 B Pharmaceuticals GmbH (DE) 2024-10-10 US disclosed
EP-4373529-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3B Pharmaceuticals GmbH (DE) 2024-05-29 EP disclosed
WO-2023002045-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2023-01-26 WO disclosed
EP-4122499-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3B Pharmaceuticals GmbH (DE) 2023-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335569-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF FIBP, FGF2, FGFR2 DPP4 510/4885MEN1 4311/4885KMT2A 3966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.